Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis
Por:
Papp K.A., Thoning H., Gerdes S., Megna M., Brandi H., Jablonski Bernasconi M.Y., Yélamos O.
Publicada:
1 ene 2022
Resumen:
Background and objectives: Once-daily, fixed-combination calcipotriol 50 µg/g (Cal) plus betamethasone dipropionate 0.5 mg/g (BD) is available in aerosol foam and cream formulations. As no head-to-head data are available, we use a matching-adjusted indirect comparison (MAIC) approach to compare Cal/BD foam and cream. Methods: Anchored and unanchored MAIC analyses were conducted using individual patient data (IPD) from five Cal/BD foam trials and two trials of Cal/BD cream. Outcomes of interest were the proportion of patients with Physician's Global Assessment (PGA) success and the mean reduction in modified Psoriasis Area and Severity Index (mPASI). Results: In the anchored MAIC, patients were more likely to achieve PGA success after 4 weeks of Cal/BD foam than after 8 weeks of Cal/BD cream and had larger mean improvements in mPASI (p <.01 in EU mPASI analysis). In unanchored analyses, 4 weeks of Cal/BD foam treatment was statistically significantly more efficacious in inducing PGA success than 8 weeks of Cal/BD cream (p <.01 in five of six comparisons). Mean reductions in mPASI were consistently statistically significantly greater with Cal/BD foam than with Cal/BD cream. Conclusions: Use of Cal/BD foam consistently shows significantly greater improvements in PGA and mPASI outcomes, compared with Cal/BD cream. © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.
Filiaciones:
Papp K.A.:
Probity Medical Research, Waterloo, ON, Canada
K Papp Clinical Research, Waterloo, ON, Canada
Thoning H.:
LEO Pharma, Ballerup, Denmark
Gerdes S.:
Center for Inflammatory Skin Diseases, Dept. of Dermatology, Venereology and Allergology, University Medical Center Schleswig-Holstein, Kiel, Germany
Megna M.:
Section of Dermatology, Dept. of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
Brandi H.:
LEO Pharma, Ballerup, Denmark
Jablonski Bernasconi M.Y.:
LEO Pharma, Ballerup, Denmark
Yélamos O.:
Dermatology Dept, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain
Dermatology Dept, Centro Médico Teknon, Quirónsalud, Barcelona, Spain
All Open Access, Hybrid Gold
|